Westdeutsches Prostatazentrum | Priv.-Doz. Dr. Dr. Holger Gerullis

Priv.-Doz. Dr. Dr. Holger Gerullis

Specialist in urology, medical tumor therapy and palliative medicine

Priv.-Doz. Dr. Dr. Gerullis has been working for over 15 years with surgical techniques for the treatment of benign prostate hyperplasia (BPH). In particular, he has gained extensive experience in the field of gentle Holmium Laser Enucleation of the Prostate (HoLEP) in recent years. His special clinical and scientific focus is on the drug therapy of all urological tumor entities as well as the evaluation and implementation of new innovative surgical techniques. He is an internationally recognized expert in these fields and author of numerous publications, book and congress contributions.

‍

Professional career

Specialist for Urology, Department of Urology, KLINIK am RING, Cologne
Specialist for Urology, West German Prostate Center, Cologne
Senior Physician, Function: Endourology, Urological University Hospital, Endourology, Oldenburg Hospital
Senior Physician, Function: Head of Clinical Research, Urological Clinic, Lukas Hospital, Neuss
Specialist, Urooncology, University Clinic for Urology, University of Düsseldorf
Senior Physician, Function: Head of Clinical Research, Urological Clinic, Lukas Hospital, Neuss
Assistant physician, Urological Clinic, Lukas Hospital, Neuss
Assistant physician, Surgical Clinic, DRK Clinics, Berlin
Resident, Helios Kliniken, Berlin Book
Study of medicine in Berlin, Barcelona, Geneva, Buenos Aires

‍

Degrees

Habilitation (Priv.-Doz.) and Venia legendi for the subject Urology "The IDEAL recommendations for the evaluation of surgical innovations - first clinical and experimental applications in urology". Carl von Ossietzky University Oldenburg
PhD (Dr.) "A new approach for improving biocompatibility of mesh implants" University of Szeged, Hungary.
Specialist for Urology - Medical Association North Rhine, Düsseldorf
PhD (Dr. med.) "Studies on the tissue distribution of TIRC7-a new T cell molecule". Humboldt University Berlin
Medical State Examination - Humboldt University of Berlin

‍

Foreign languages

English
French
Spanish
Portuguese

‍

Priv.-Doz. Dr. Dr. Holger Gerullis is a member of the following organizations:

German Society for Urology (DGU)
European Association of Urology (EAU)
West German Prostate Center

54 Kadhum T, Selinski S, Blaszkewicz M, Reinders J, Roth E, Volkert F, Ovsiannikov D, Moormann O, Gerullis H, Barski D, Otto T, Höhne S, Hengstler JG, Golka K. Bladder cancer course, four genetichigh-risk variants, and histopathological findings. EXCLI J. 2023 Aug 18;22:867-879

53 Gleichenhagen J, Arndt C, Casjens S, Töpfer C, Gerullis H, Raiko I, Taeger D, Ecke T, Brüning T, Johnen G. Exploring solid-phase proximity ligation assay for survivin detection in urine. PLoS One. 2022 Jun 29;17(6):e0270535.

52 Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz PI, Salomon G, Wiggermann P, Hammerer P, Schiffmann J. 8Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Urol Int. 2022;106(1):56-62.

51. Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H , Karakiewicz P, Salomon G, Wiggermann P, Hammerer P, Schiffmann J. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Urol Int. 2021 May 7;1-7.

50. Steinwender T, Manka L, Grindei M, Tian Z, Winter A, Gerullis H, Karakiewicz PI, Hammerer P, Schiffmann J. Elastography Targeted Prostate Biopsy in Patients under Active Surveillance. Urol Int. 2020;104(11-12):948-953.

49. Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. World J Urol. 2020 Dec;38(12):3085-3090.

48. Barski D, Gerullis H, Ecke T, Boros M, Brune J, Beutner U, Tsaur I, Ramon A, Otto T. Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. Adv Ther. 2020 Jan;37(1):592-602.

47. Kokov D, Manka L, Beck A, Winter A, Gerullis H, Karakiewicz PI, Hammerer P, Schiffmann J. Only Size Matters in Stone Patients: Computed Tomography Controlled Stone-Free Rates after Mini-Percutaneous Nephrolithotomy. Urol Int. 2019;103(2):166-171.

46. Geißen W, Engels S, Aust P, Schiffmann J, Gerullis H, Wawroschek F, Winter A. Diagnostic Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy After Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Intermediate- and High-Risk Prostate Cancer Using the Magnetic Activity of Sentinel Nodes. Front Pharmacol. 2019 Oct 11;10:1123.

45. Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. J Cancer. 2018 Mar 29;9(8):1337-1348.

44. Ecke TH, Weiß S, Stephan C, Hallmann S, Arndt C, Barski D, Otto T, Gerullis H. UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for
Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter Study. Int J Mol Sci. 2018 Dec
2;19(12):3841.

43. Winter A, Kowald T, Paulo TS, Goos P, Engels S, Gerullis H, Schiffmann J, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node
imaging and magnetometer-guided intraoperative detection in prostate cancer using superparamagnetic iron oxide nanoparticles. Int J
Nanomedicine. 2018 Oct 23;13:6689-6698.

42. Winter A, Engels S, Goos P, Süykers MC, Henke RP, Gerullis H, Wawroschek F. Detection of CK19 mRNA Using One-step Nucleic Acid Amplification (OSNA) in Prostate Cancer: Preliminary Results. J Cancer. 2018 Nov 24;9(24):4611-4617.

41. Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T, Johnen G. Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine. Int J Mol Sci. 2018 Jan 11;19(1).

40. Winter A, Engels S, Reinhardt L, Wasylow C, Gerullis H, Wawroschek F. Magnetic Marking and Intraoperative Detection of Primary Draining Lymph Nodes in High-Risk Prostate Cancer Using Superparamagnetic Iron Oxide Nanoparticles: Additional Diagnostic Value. Molecules. 2017 Dec 9;22(12).

39. Selinski S, Blaszkewicz M, Ickstadt K, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Moormann O, Banfi G, Nyirady P, Vermeulen SH, Garcia-Closas M, Figueroa JD, Johnson A, Karagas MR, Kogevinas M, Malats N, Schwenn M, Silverman DT, Koutros S, Rothman N, Kiemeney LA, Hengstler JG, Golka K. Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis. 2017 Dec 7;38(12):1167-1179.

38. winter A, Kneib T, Wasylow C, Reinhardt L, Henke RP, Engels S, Gerullis H, Wawroschek F. Updated Normogram Incorporating Percentage of Positive Cores to Predict Probability of Lymph Node Invasion in Prostate Cancer Patients Undergoing Sentinel Lymph Node Dissection. J Cancer. 2017 Aug 22;8(14):2692-2698

37. Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Hengstler JG, Otto T, Golka K. Nacetyltransferase 1*10 genotype in bladder cancer patients. J Toxicol Environ Health A. 2017;80(7-8):417-422.

36. Barski D, Gerullis H, Ecke T, Yang J, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Bladder Reconstruction with Human Amniotic Membrane in a Xenograft Rat Model: A Preclinical Study. Int J Med Sci. 2017 Mar 11;14(4):310-318.

35. Ecke TH, Barski D, Weingart G, Lange C, Hallmann S, Ruttloff J, Wawroschek F, Gerullis H. Presentation of a method at the Exploration Stage according to IDEAL: Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia is a feasible and effective method - retrospective analysis of 439 patients. Int J Med Sci. 2017 Feb 25;14(4):302-309.

34. Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Human Amniotic Membrane Is Not Suitable for the Grafting of Colon Lesions and Prevention of Adhesions in a Xenograft Rat Model. Surg Innov. 2017 Aug;24(4):313-320

33. Ecke TH, Weiß S, Stephan C, Hallmann S, Barski D, Otto T, Gerullis H. UBC Rapid Test for detection of carcinoma in situ for bladder cancer. Tumour Biol. 2017 May;39(5):1010428317701624.

32. Barski D, Gerullis H, Ecke T, Kranz J, Schneidewind L, Leistner N, Queissert F, Mühlstädt S, Grabbert M, Tahbaz R, Pelzer AE, Joukhadar R, Klinge U, Boros M, Bader W, Naumann G, Puppe F, Otto T. Registry of implants for the reconstruction of pelvic floor in males and females: A feasibility case series. Int J Surg. 2017 Jun;42:27-33.

31. Gerullis H, Ecke TH, Barski D, Bantel C, Weyland A, Uphoff J, Jansen T, Wawroschek F, Winter A. Retrospective analysisof a surgical innovation using the IDEAL framework: radical cystectomy with epidural anesthesia. J Int Med Res. 2017 Apr;45(2):714-722.

30. Gerullis H, Barski D, Georgas E, Borós M, Ramon A, Ecke TH, Selinski S, Luedders D, Kramer MW, Winter A, Wawroschek F, Otto T. Protocol for a Randomized Phase II Trial for Mesh Optimization by Autologous Plasma Coating in Prolapse Repair: IDEAL Stage 3. Adv Ther. 2017 Apr;34(4):995-1006.

29. Gerullis H, Schwartmann K, Ecke TH, Georgas E, Herberg P, Winter A, Wawroschek F, Barski D, Otto T. Transvesical Suprapubic Externalization of Ureteral Stents - Introduction of a Surgical Method at the Development Stage. Urol Int. 2017;99(1):69-76.

28. Barski D, Arndt C, Gerullis H, Yang J, Boros M, Otto T, Kolberg HC. Transvaginal PVDF-mesh for cystocele repair: a cohort study. Int J Surg. 2017 Mar;39:249-254.

27. Ecke TH, Huang-Tiel HJ, Golka K, Selinski S, Geis BC, Koswig S, Bathe K, Hallmann S, Gerullis H. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. Int J Mol Sci. 2016 Nov 10;17(11). pii: E1879.

26. Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Winter A, Bagner JW, Otto T. Repair of a vesico-vaginal fistula with amniotic membrane - Step 1 of the IDEAL rcommendations of surgical innovation. Cent European J Urol. 2015;68(4):459-61.

25. Figueroa JD, Middlebrooks Gerullis H et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016 Mar 15;25(6):1203-14.

24. Ecke TH, Arndt C, Stephan C, Hallmann S, Lux O, Otto T, Ruttloff J, Gerullis H. Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer Anticancer Res. 2015 May;35(5):2651-5.

23. Barski D, Gerullis H, Georgas E, Bär A, Lammers B, Ramon A, Ysebaert D, Klosterhalfen B, Boros M, Otto T. Coating of mesh grafts for prolapse and urinary incontinence repair with autologous plasma: exploration stage of a surgical innovation. Biomed Res Int. 2014;2014:296498

22. Rafnar T, Sulem P, Gerullis H et al. Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Hum Mol Genet. 2014 Oct 15;23(20):554557

21. Gerullis H, Georgas E, Borós M, Klosterhalfen B, Eimer C, Arndt C, Otto S, Barski D, Ysebaert D, Ramon A, Otto T. Inflammatory reaction as determinant of foreign body reactions is an early and susceptible event after mesh implantation. Biomed Res Int. 2014;2014:510807.

20. Gerullis H, Georgas E, Eimer C, Arndt C, Barski D, Lammers B, Klosterhalfen B, Borós M, Otto T. Coating with autologous plasma improves biocompatibility of mesh grafts in vitro: development stage of a surgical innovation. Biomed Res Int. 2013;2013:536814

19. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy Anticancer Drugs. 2013 Apr;24(4):422-5

18. Gerullis H, Klosterhalfen B, Borós M, Lammers B, Eimer C, Georgas E, Otto T. IDEAL in meshes for prolapse, urinary incontinence and hernia repair. Surg Innov. 2013 Oct;20(5):502-8

17. Gerullis H, Eimer C, Georgas E, Homburger M, El-Baz AG, Wishahi M, Borós M, Ecke TH, Otto T. Muscle-derived cells for treatment of iatrogenic sphincter damage and urinary incontinence in men. ScientificWorldJournal. 2012;2012:898535.

16. Ecke TH, Hallmann S, Koch S, Ruttloff J, Cammann H, Gerullis H, Miller K, Stephan C. External validation of an artificial neural network and two normograms for prostate cancer detection. ISRN Urol. 2012;2012:643181

15. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Volkert F, Ebbinghaus R, Prager HM, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Hartel M, Weistenhöfer W, Schöps W, Rizvi SA, Aslam M, Bánfi G, Romics I, Ickstadt K, Hengstler JG, Golka K. Rs11892031>A@ on chromosome 2q37 in an intronic region oft he UGT1A locus is associated with urinary bladder cancer risk. Arch Toxicol. 2012 Sep;86(9):1369-78.

14 Gerullis H, Georgas E, Eimer C, Goretzki PE, Lammers BJ, Klosterhalfen B, Boros M,Wishahi M, Heusch G, Otto T. Evaluation of Biocompatibility of Alloplastic Materials: Development of a Tissue Culture In Vitro Test System. Surg Technol Int. 2011 Dec;21:21-7.

13. Gerullis H, Georgas E, Quast S, Eimer C, Homburger M, Orzechowski D, Altindag M, Rübben H, Otto T. Early endoscopic detection and subsequent removal of sphincter penetrating anastomotic sutures may prevent irreversible urinary incontinence after radical prostatectomy. J Endourol. 2012 Jul;26(7):889-94.

12. Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, Arndt C, Heusch C, Otto T. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol. 2012 Dec;29(4):2870-6.

11. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Volkert F, Ebbinghaus R, Prager HM, Lukas C, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Hartel M, Weistenhöfer W, Schöps W, Rizvi SA, Aslam M, Bánfi G, Romics I, Ickstadt K, Hengstler JG, Golka K. Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. Arch Toxicol. 2012 Feb;86(2):195-203

10 AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Gerullis H, et al. European genome-wide association study identifies SLC14A1 as new urinary bladder cancer susceptibility gene. Hum Mol Genet. 2011 Nov 1;20(21):4268-81

9 Gerullis H, Quast S, Eimer C, Bagner JW, Otto T. Sphincter lesions after radical prostatectomy-evaluation and classification. J Endourol. 2011 Jun;25(6):1075-80.

8. Lehmann ML, Selinski S, Blaszkewicz M, Orlich M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Dietrich H, Ebbinghaus R, Prager HM, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Löhlein D, Weistenhöfer W, Schöps W, Beg AE, Aslam M, Bánfi G, Romics I, Ickstadt K, Schwender H, Winterpacht A, Hengstler JG, Golka K. Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch Toxicol. 2010 Dec;84(12):967-78.

7. Ecke TH, Gerullis H, Heuck CJ, Bartel P, Hallmann S, Koch S, Ruttloff J. Does a new ultrasound probe change the complication rates of transrectal ultrasound-guided needle biopsies oft he prostate? Anticancer Res. 2010 Jul;30(7):3071-6

6 Gerullis H, Ecke TH, Schwartmann K, Heuck CJ, Eimer C, Bagner JW, Kocheril S, Otto T. Nephrocutaneous bypass in ureteral obstruction. Urology. 2010 Aug;76(2):4805

5. corner TD, Gerullis H, Bartel P, Koch S, Ruttloff J. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. Minerva Urol Nefrol. 2009 Sep;61(3):249-56

4. Ecke TH, Gerullis H, Bartel P, Koch S, Ruttloff J. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma oft he urothelium. Minerva Urol Nefrol. 2009 Mar;61(1):1-8

3 Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol. 2010 Jun;27(2):373-8

2 Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol. 2009 May;63(6):1097-102

Gerullis H, Kuemmel C, Popken G. Laparoscopic cystectomy with extracorporeal-assisted urinary diversion: experience with 34 patients. Eur Urol. 2007 Jan;51(1):193-8

Reviews, Case reports, Letters in Journals

30. Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Human amniotic membrane dressing for the treatment of an
infected wound due to an entero-cutaneous fistula: Case report. Int J Surg Case Rep. 2018;51:11-13.

29. Selinski S, Blaszkewicz M, Ickstadt K, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Moormann O, Banfi G, Nyirady P, Vermeulen SH, Garcia-
Closas M, Figueroa JD, Johnson A, Karagas MR, Kogevinas M, Malats N, Schwenn M, Silverman DT, Koutros S, Rothman N, Kiemeney LA, Hengstler JG, Golka K. Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis. 2017 Dec 7;38(12):1167-1179.

28. Selinski S, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Salem J, Moormann O, Geis BC, Niedner H, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-acetyltransferase 2 Is Associated with recurrence-free Time in Bladder Cancer Patients. Eur Urol. 2017 Jun;71(6):994-995

27. Gerullis H, Eitzen A, Uphoff J, Daaboul F, Chavan A, Ermert L, Wawroschek F, Winter A. Recurrent symphysitis culminating in pelvic ring fracture after hyperextended transurethral prostate resection and vaporization with symphysis erosion: a case report. J Med Case Rep. 2017 May 19;11(1):141

26. Barski D, Gerullis H, Otto T. Review of surgical implant procedures for male incontinence after radical prostatectomy according to IDEAL framework. Updates Surg. 2017 May 6. doi: 10.1007/s13304-017-0460-x. [Epub ahead of print]

25 Gerullis H, Barski D, Malmström PU, Sun X, Ecke TH. Evidence in urologic- and pelvic-surgery research: finding the IDEAL way of reporting. Biomed Res Int. 2017;2017:2716759

24. Winter A, Engels S, Kowald T, Paulo TS, Gerullis H, Chavan A, Wawroschek F. Magnetic Sentinel Lymph Node Detection in Prostate Cancer after intraprostatic Injection of Supermagnetic Iron Oxide Nanoparticles. Current Urol. 2017 Apr;48(2):132-139

23 Gerullis H, Wawroschek F, Köhne CH, Ecke TH. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol. 2017 Jan;9(1):28-35

22. Barski D, Georgas E, Gerullis H, Ecke T. Metastatic penile carcinoma - an update on the current diagnosis and treatment options. Cent European J Urol 2014;67(2):126-32.

21. Barski D, Otto T, Gerullis H. Systematic review and classification of complications after anterior, posterior, apical and total vaginal mesh implantation for prolapse repair. Surg Technol Int. 2014 Mar;24:217-24.

20 Gerullis H, Georgas E, Bagner JW, Eimer C, Otto T. Construction of a penoid after penectomy using a transposed testicle. Urol Int. 2013;90(2):240-2

19 Gerullis H, Otto T, Ecke TH. Targeted agents in second-line bladder cancer therapy. Anticancer Drugs. 2012 Nov;23(10):1003-15

18. Golka K, Abreu-Villaca Y, Anbari Attar R, Angeli-Greaves M, Aslam M, Basaran N, Belik R, Butryee C, Dalpiaz O, Dzhusupov K, Ecke TH, Galambos H, Galambos H, Gerilovica H, Gerullis H, Gonzalez PC, Goossens ME, Gorgishvili-Hermes L, Heyns CF, Hodzic J, Ikoma F, Jichlinski P, Kang BH, Kiesswetter E, Krishnamurthi K, Lehmann ML, Martinova I, Mittal RD, Ravichandran B, Romics I, Roy B, Rungkat-Zakaria F, Rydzynski K, Scutaru C, Shen J, Soufi M, Toguzbaeva K, Vu Duc T, Widera A, Wishahi M, Hengstler JG. Bladder cancer documentation of causes: multilingual questionnaire, `bladder cancer doc. Front Biosci (Elite Ed). 2012 Jun 1;4:2709-22

17. Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, Oniani J, Otto T. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platinum resistance. Anticancer Drugs. 2011 Oct;22(9):940-3

16. Gerullis H. Vinflunine: a flourinated vinca alkaloid for bladder cancer therapy. Drugs Today (Barc). 2011 Jan;47(1):17-25

15 Gerullis H, Ecke TH, Wishahi M, Georgas E, Eimer C, Otto T. What happens if nothing happens? History of an untreated urothelial carcinoma of the bladder. J Egypt Soc Parasitol. 2010 Dec;40(3):789-96.

14 Corner TH, Gerullis H, Heuck CJ, Hallmann S, Lange C, Ruttloff J. Idiopathic giant abdominal lymph cyst: a case report. J Med Case Rep. 2011 Jan 19;5:21

13. Eimer C, Gerullis H, Heuck C, Otto T. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome? Anticancer Drugs. 2011 Jan;22(1):18-23

12. Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T. Vinflunine as second-line treatment in platinum-resistant metatsatic urothelial carcinoma: a review. Anticancer Drugs. 2011 Jan;22(1):9-17

11. Gerullis H, Ecke TH, Eimer C, Heuck CJ, Otto T. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review. Minerva Urol Nefrol. 2010 Dec;62(4):411-23

10 Gerullis H, Heuck CJ, Schneider P. Breast pseudotumoral radionecrosis as a late radiation-induced injury: a case report. J Med Case Rep. 2009 Oct 8;3:71.

9. Ecke TH, Hallmann S, Gerullis H, Ruttloff J. Reconstruction of the urethra with Surgisis onlay patch in urethral reconstructive surgery: two case reports. J Med Case Rep. 2009 Mar 16;3:7232.

8 Otto T, Gerullis H, Theuerkauf I. Re: White et al: Comparative analysis of surgical margins between radical retropubic prostatectomy and RALP: Are patients sacrificed during initiation of robotic program? (Urology 2009;73:567-571) Urology. 2009 Aug;74(2):475-6

7 Otto T, Eimer C, Gerullis H. Temsirolimus in renal cell carcinoma. Transplant Proc. 2008 Dec;40(10 Suppl):S36-9.

6. Gerullis H, Eimer C, Betz D, Otto T. Successful transureteropyelostomy after heminephrectomy of a bilateral hydronephrotic horseshoe kidney: a case report. J Med Case Rep. 2008 Jul 16;2:231

5. Otto T, Theuerkauf I, Tscheuschner S, Janusch B, Gerullis H. Targeted therapy in uro-oncology. German Journal of Oncology 2009, 41 (1), pp. 10-14.

4 Otto T, Gerullis H, Musch A. Temsirolimus - mTOR as a new target in the therapy of advanced renal cell carcinoma. AMT, Drug Therapy, 26th Year Issue 8, August 2008, 275-283.

3, Eimer C, Gerullis H, Otto T. Targeted therapy of metastatic renal cell carcinoma (mRCC). Oncopipeline, 2008;1:82-90.

2 Otto T, Bagner JW, Eimer C, Gerullis H, Ramon A. Restoration of the bladder sphincter with autologous muscle cells for continence. Uro-News 2008, (11) 24-28

Gerullis H, Otto T. Vinflunine (Javlor). Second-line therapy for metastatic urothelial carcinoma after failure of platinum-containing first-line therapy. Internistische Praxis, 2012 Vol. 52 Issue 3, p. 629.

Book contributions

21 Otto T, Eimer C, Gerullis H. Standards in renal tumor treatment. In: Otto T (ed.): mTOR inhibition - A new mechanism of action in oncology, 1st edition, Bremen: UNI-MED, 2009: 40-51, ISBN 978-3-8374-2019-7.

20 Gerullis H, Eimer C, Maute L, Bergmann L. Experiences from the Temsirolimus Compassionate Use Program. In: Otto T (ed.): mTOR inhibition - A new mechanism of action in oncology, 1st edition, Bremen: UNI-MED, 2009: 66-73, ISBN 9783-8374-2019-7.

19 Eimer C, Wishahi M, Kretschmar T, Gerullis H. Quality of life. In: Otto T (ed.): mTOR inhibitors - update 2011, 2nd edition, Bremen: UNI-MED, 2011: 116-123, ISBN 978-3-8374-2158-3.

18. Otto T, Gerullis H, Gibbons J, Schmidinger M. mTOR inhibitors in research and practice.In: Otto T (ed.): mTOR inhibitors - Update 2013, 3rd edition, Bremen: UNIMED, 2013:13-22, ISBN 978-3-8374-2158-3.

17. Gerullis H, Niegisch G. mTOR inhibition in urothelial carcinoma.In: Otto T (ed.): mTOR inhibitors - Update 2013, 3rd edition, Bremen: UNI-MED, 2013: 111-114, ISBN 978-3-8374-2158-3.

16. Gerullis H, Winter A. IDEAL - way out of the dilemma? In: Otto T, Lammers BJ, Schumpelick V (eds.) Implants in Surgery - Update 2015. UNI-MED, Bremen. 1st ed. 2015: 103-6. ISBN-10: 383741454X.

15. Barski D, Bagner JW, Gerullis H, Otto T. Alloplastic meshes and their surgical removal in case of complications. In: Hoffmann R, Wagner U (eds.): Incontinence and Descensus Surgery in Women. 2nd edition, Springer Verlag 2015: 219-229, ISBN 978-3-66243671-4.

14 Bremer J, Schenck M, Gerullis H, Otto T. Renal cell carcinoma. In: Rübben H, Otto T (eds): Colloquium Urology 2010, 1st edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2010: 73-104, ISBN 978-3-939415-08-4.

13 Otto T, Becker M, Börgermann C, Bremer J, vom Dorp F, Eimer C, Gerullis H, Hess J, Jäger T, Janusch B, Pelzer N, Peschkes C, Quast S, Schenck M, Tschirdewahn S. Urolooncology. In: Rübben H, Otto T (eds): Colloquium Urology 2011, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2011: 5-131, ISBN 9783-939415-11-4.

12 Otto T, Gerullis H, Eimer C, Hess J, Pelzer N, Börgermann C. Prostate carcinoma. In: Rübben H, Otto T (eds): Colloquium Urology 2012, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 89-142, ISBN 978-3-939415-14-5.

11 Otto T, Gerullis H, Eimer C, Tschirdewahn S, vom Dorp F, Becker M. Carcinoma of the urinary bladder. In: Rübben H, Otto T (eds): Colloquium Urology 2012, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 143-172, ISBN 978-3939415-14-5.

10 Otto T, Gerullis H, Eimer C, Bremer J, Schenck M. Renal cell carcinoma. In: Rübben H,

9th Otto T (ed.): Colloquium Urology 2012, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 173-194, ISBN 978-3-939415-14-5.

8 Otto T, Gerullis H, Eimer C, vom Dorp F. Tumors of the male genitalia. In: Rübben H, Otto T (eds): Colloquium Urology 2012, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 195-202, ISBN 978-3-939415-14-5.

7 Otto T, Gerullis H, Eimer C. Rare tumors. In: Rübben H, Otto T (eds): Colloquium Urology 2012, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 203-208, ISBN 978-3-939415-14-5.

6th Bremer J, Schenck M, Gerullis H, Eimer C, Otto T. Renal cell carcinoma. In: Rübben H, Otto T (eds): Colloquium Urology 2013, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2013: 141-166, ISBN 978-3-939415-17-6.

5 Vom Dorp F, Eimer C, Gerullis H, Otto T. Tumors of the male genitalia. In: Rübben H, Otto T (eds): Colloquium Urology 2013, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2013: 167-176, ISBN 978-3-939415-17-6.

4 Barski D, Gerullis H. Implants in urogynecology - Quo vadis. In: Rübben H, Otto T (eds): Colloquium Urology 2015, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2015:17-30, ISBN 978-3-939415-24-4.

3 Barski D, Gerullis H. Plea for a registry in implant medicine. In: Rübben H, Otto T (eds): Colloquium Urology 2016, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2016: 39-46, ISBN 978-3-939415-27-5.

2 Otto T, Yang J, Gerullis H, Hubens G. Carcinoma of the urinary bladder. In: Rübben H, Otto T (eds): Colloquium Urology 2016, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2016: 86-100, ISBN 978-3-939415-27-5.

1 Otto T, Schenck M, Gerullis H, Ramon A, Timmermans JP, Ponsaerts P. Renal cell carcinoma. In: Otto T, Steffens JA, Rübben H (eds): Colloquium Urology 2017, 2nd edition, Munich: Agileum Verlag und Gesundheitsakademie GmbH, 2017: 25-46,

ISBN 978-3-939415-39-5

Selected citable abstracts

Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW. Real-world survival outcomes in patients with advanced urothelial cancer in Germany. Ann Oncol 2017; 28 (Suppl 5) 1117p.

Gerullis H, Ecke TH, Bantel C, Weyland A, Barski D, Jansen T, Uphoff J, Wawroschek F, Winter A. Radical cystectomy in epidural anaesthesia - Feasibility analysis using a new reporting method following the IDEAL recommendations. Int J Surg 2016; 36 (Suppl 2):137.

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans JP, Ramon A, Boros M, Varga G, Otto T. Reconstruction of bladder defects with amniotic membrane - IDEAL-D Stage 0-1. Int J Surg 2016; 36 (Suppl 2):136.

Gerullis H, Barski D, Ecke TH, Eimer C, Boros M, Klosterhalfen B, Ramon A, Otto T. Autologous plasma coating improves biocompatibility of mesh implants. On the IDEAL way from bench to bedside. Int J Surg 2016; 36 (Suppl 2):142

Ecke TH, Weingart G, Lange C, Hallmann S, Wawroschek F, Barski D, Ruttloff J, Gerullis H. Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia with and without stand-by anesthesia - Complication rates and clinical outcome for a method at the exploration stage according to IDEAL. Int J Surg 2016; 36 (Suppl 2):142

Barski D, Gerullis H, Ecke T, Joukhadar R, Kranz J, Tahbaz R, Queissert F, Schneidewind L, Mühlstädt S, Grabbert M, Huppertz N, Pelzer AE, Klinge U, Boros M, Bader W, Puppe W, Otto T. Development of an online platform for registration and outcome measurement of urogynecological implants according to IDEAL-system. Int J Surg 2016; 36 (Suppl 2):141-142

Winter A, Kowald T, Paulo T, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: the first in-human results. Urologist A 2016; 55 (Suppl 1):47.

Winter A, Engels S, Goos Ph, Süykers MC, Gudenkauf S, Henke RP, Gerullis H, Wawroschek F. Magnetometer guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in intermediate and high risk prostate cancer patients. Urologist A 2016; 55 (Suppl 1):72.

Winter A, Engels S, Goos Ph, Süykers MC, Gudenkauf S, Henke RP, Gerullis H, Barski D, Wawroschek F. Magnetometer guided sentinel lymphadenectomy after intraprostatic injection of super-paramagnetic iron oxide nanoparticles in intermediary and high risk prostate cancer patients. J Urol 2016; 195 (4, Suppl):e987.

Winter A, Kowald T, Paulo TS, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: the first in-human results. Eur Urol Suppl 2016; 15(3):1060.

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans JP, Ramon A, Boros M, Varga G, Otto. Augmentation of rat bladder with human amniotic membrane graft. Eur Urol Suppl 2016; 15(3):e1027.

Höhne, S, Gerullis H, Blaszkewicz M, Selinski S, Niedner H, Hengstler JG, Golka K, Otto T. Influence of N-acetyltransferase 1*10 genotype on urinary bladder carcinoma risk. 62nd Congress of the North Rhine-Westphalian Society of Urology: meeting abstracts, Münster, April 14-15, 2016 (p. DocP3.6). Düsseldorf: German Medical Science GMS Publishing House, 2016.

Selinski S, Geis B, Gerullis H, Otto T, Niedner H, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-acetyltransferase 2 (NAT2) and prognosis in bladder cancer patients Naunyn-Schmiedeberg's Arch. Pharmacol. 389 (Suppl 1): S57 (2016)

Winter A, Engels S, Goos P, Süykers MC, Gudenkauf S, Henke RP, Gerullis H, Wawroschek F. Magnetometer guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in intermediate- and high-risk prostate cancer patients. J Urol Suppl (2016), Vol 195, Issue 4, e987.

Winter A, Kowald T, Paulo T, Goos P, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of supermagnetic iron oxide nanoparticles: The first in-human results. Eur Urol Suppl (2016) Vol.15, Issue 3, e1060.

Ecke T, Arndt C, Gützlaff S, Stephan C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. Detection of carcinoma in situ (CIS) of urinary bladder cancer using UBC® Rapid as tumour marker. Eur Urol Suppl. (2016), Vol.15, Issue 3, e750

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans J-P, Ramon A, Boros M, Varga G, Otto T. Augmentation of rat bladder with human amniotic membrane graft. Eur Urol Suppl. (2016) Vol.15, Issue 3, e1027.

Ecke TH, Arndt C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. New Results of a Multicentre-study for UBC rapid as Marker for Urinary Bladder Cancer. Tumor Biol 2015; 36 (Suppl 1): S56

Gerullis H, Georgas E, Barski D, Boros M, Klosterhalfen B, Lammers B, Eimer C, Ramon A, OttoT. A novel approach for assessment and improvement of surgical meshes. Hernia 2014, Vol 18, Suppl 2 , P171

Gerullis H, Boros M, Klosterhalfen B, Heusch G, Georgas E, Eimer C, Otto T. Improving bioperformance of meshes for SUI and POP by coating with autologous plasma - results of a long term aninmal study. Eur Urol Suppl. (2013) Vol. 12, Issue 1, e251

Gerullis H, Eimer C, Georgas E, Bagner JW, Otto T. Temsirolimus in platinum-resistant metastatic urothelial cancer: a phase II trial. J Clin Oncol 30, no.5 suppl (2012) 302-302.

Gerullis H, Eimer C, Georgas E, Otto T. Temsirolimus in Second-Line Metastatic Urothelial Cancer - A Phase II Trial. Eur Urol Suppl. (2012), Vol. 11, Issue 4, p117

Gerullis H, Eimer C, Georgas E, Lammers B, Goretzki P, Klosterhalfen B, Boros M, Ramon A, Otto T. Improved biocompatibility of meshes used for hernia, incontinence and organ prolapse repair by plasma coating - results of in vitro and in vivo studies.

Eur Urol Suppl. (2012), Vol. 11, Issue 1, e1068.

Gerullis H, Georgas E, Eimer C, Lammers B, Goretzki P, Klosterhalfen B, Boros M, Ramon A, Otto T. Evaluation of biocompatibility of alloplastic materials - development of a tissue culture in vitro test system. Eur Urol Suppl. (2012), Vol. 11, Issue 1, e807.

Gerullis H, Eimer C, Ramon A, Wishahi M, Heusch G, Klosterhafen B, Boros M, Bagner J, Otto T. Improved Biocompatibility of Meshes used for Hernia, Incontinence and Organ Prolapse Repair by Plasma Coating - Results of in in vitro an din vivo Studies. J Urol Suppl. (2011) Vol. 185, Issue 4, e317.

Eimer C, Quast S, Gerullis H, Otto T. Prevention of Urinary Stress Incontinence Caused by Radical Retropubic Prostatectomy (RRP) by Early Endoscopic Removal oft he Anastomosis Sutures. J Urol Suppl (2010), Vol 183, Issue 4, e618.

Eimer C, Gerullis H, Karig R, Goretzki P, Otto T. Therapy of Refractory Postoperative.

Urinary Stress Incontinence by the Use of Autologous Skeletal Muscle-Derived Cells (MDC). J Urol Suppl. (2010), Vol 183, Issue 4, e587.

Gerullis H, Eimer C, Karig R, Goretzki P, Ramon A, Otto T. Therapy of Refractory Postoperative Stress Urinary Incontinence by the Use of Autologous Skeletal MuscleDerived Cells (MDC). Eur Urol Suppl. (2010), Vol. 9, Issue 2, p329

Eimer C, Gerullis H, Bagner J, Lammers BJ, Theuerkauf, I Ramon A, Otto T. In Vitro Test System for the Evaluation of the Biocompatibility of Alloplastic Materials. Eur Urol Suppl. (2010) Vol. 9, Issue 2, p109

Eimer C, Quast S, Gerullis H, Otto T. Evaluation and Classification of Sphincter Lesions due to Radical Prostatectomy (RP). Eur Urol Suppl. (2010) Vol. 9, Issue 2, p105.

Eimer C, Quast S, Gerullis H, Otto T. Prevention of Urinary Stress Incontinence Caused by Radical Reropubic Prostatectomy (RRP) by Early Endoscopic Removal oft he Anastomosis Sutures. J Urol Suppl (2010) Vol. 183, Issue 4, e618.

Eimer C, Gerullis H, Karig R, Goretzki P, Ramon A, Otto T. Therapy of Refractory Postoperative Stress Incontinence by the Use of Autologous Skeletal Muscle-Derived.

Cells (MDC). J Urol Suppl. (2010), Vol. 183, Issue 4, e587.

Bagner J, Gerullis H, Karig R, Ramon A, Otto T. In vitro test system for the evaluation of the biocompatibility of alloplastic materials and improvement by autologous coating. Urology Suppl (2010),Vol.76, Issue 3, S21-S22.

Karig R, Bagner J, Gerullis H, Eimer C, Ramon A, Otto T. Treatment of refractory postoperative urinary stress incontinence by the use of autologous satellite cells (SLC). Urology Suppl (2010),Vol.76, Issue 3, S1

Karig R, Bagner J, Gerullis H, Eimer C, Quast S, Otto T. evaluation and classification of sphincter lesions due to radical prostatectomy (RP). Urology Suppl (2010),Vol.76, Issue 3, S77.

Gerullis H, Bergmann L, Maute L, Bagner J, Eimer C, Otto T. Experiences and Practical Conclusions Concerning Temsirolimus USe and Adverse Event Management in Advanced Renal Cell Carcinoma Within a Compassionate USe Program in Germany. Urology Suppl (2009),Vol.74, Issue 4, S261

Gerullis H, Bergmann L, Maute L, Ecke T, Eimer C, Bagner J, Otto T. Feasibility of Sequential Use of Sunitinib and Temsirolimus in Advanced Renal Cell Carcinoma. Urology Suppl (2009),Vol.74, Issue 4, S261

Gerullis H, Eimer C, Bagner J, Tscheuschner S, Otto T. Repair of Iatrogenic Sphincter.

Damage and Urinary Incontinence by Autologous Skeletal Muscle Derived Cells (MDC). Urology Suppl (2009),Vol.74, Issue 4, S2

Gerullis H, Eimer C, Bagner J, Otto T. In Vitro Test Pattern for Determination of Biocompatibility of Alloplastic Materials Used for Treatment of Urinary Incontinence. Urology Suppl (2009),Vol.74, Issue 4, S232

Gerullis H, Tscheuschner S, Eimer C, Bagner J, Otto T. Radical Prostatectomy and Sphincter Damage. What Can We Learn from the Pitfalls. Urology Suppl (2009),Vol.74, Issue 4, S2

Otto T, Eimer C, Gerullis H. Sphincter Repair with autologous Skeletal Muscle Derived Cells (MDC) - What do we transplant? Eur Urol Suppl. (2008) Vol. 7, Issue 3, p317 Otto T, Eimer C, Gerullis H. Repair of iatrogenic Sphincter Damage and Urinary Incontinence by autologous Skeletal Muscle Derived Cells (MDC). Eur Urol Suppl. (2008) Vol. 7, Issue 3, p87.

Otto T, Eimer C, Gerullis H. Repair of Iatrogenic Sphincter Damage and Urinary Incontinence by Autologous Skeletal Muscle Derived Cells (MDC). J Urol Suppl. (2008), Vol 179, Issue 4, p 484.

Otto T, Eimer C, Gerullis H. Experience with the German "Compassionate Use Program" (CUP) for Temsirolimus (TEMSR) in Patients with Advanced Renal Cell Carcinoma (RCC). Eur Urol Suppl (2008) Vol. 7, Issue 3, p308

Otto T, Tscheuschner S, Eimer C, Gerullis H, Schwartmann K, Bagner J. Radical Prostatectomy (RP) and Sphincter Damage - What can we learn from the Pitfalls? Eur Urol Suppl. (2008) Vol. 7, Issue 3, p88

Otto T, Eimer C, Bagner J, Gerullis H, Schwartmann K, Bornemeyer K. Tissue engineering with autologous unipotent skeletal muscle cells in external sphincter insufficiency III. Eur Urol Suppl. (2007) Vol. 6, Issue 2, p73.

Selected presentations at scientific congresses

Selinski S, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Salem J, Moormann O, Geis BC, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-acetyltransferase 2 ("NAT") genotype and recurrence-free survival of bladder cancer patients. 11th Northern Congress of Urology, Rostock-Warnemünde. 2017, 6/15-17, HF 10.1.

Barski D, Puppe F, Klinge U, Joukhadar R, Gerullis H, Otto T. German register of urogynecological implants - first results. Annual Meeting of the International urogynecological association (IUGA), Nice, 2016, Abstract 176.

Winter A, Kowald T, Paulo T, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results. 68th Congress of the German Society of Urology, Leipzig. 2016, 28.09.-1.10.

Gerullis H, Ecke T, Bantel C, Weyland A, Barski D, Uphoff J, Winter A, Wawroschek F. Radical cystectomy under epidural anesthesia - feasibility study using a new imaging method according to IDEAL recommendation. Nordkongress Urologie, Berlin. 2016, 16.-18.6.

Winter A, Kowald T, Paulo TS, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles. ISNS Biannual Meeting, Milan. 2016, 30.04.-02.05.

Winter A, Kowald T, Paulo TS, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results. EAU Annual Congress, Munich. 2016, 11.-15.3.

Wawroschek F, Winter A. Oldenburg Experience. Consensus Meeting Sentinel Node Procedure in Prostate Cancer, Berlin. 2016, 25.-26.02.

Gerullis H, Ecke T, Bantel C, Weyland A, Barski D, Uphoff J, Winter A, Wawroschek F. Radical cystectomy under epidural anesthesia - feasibility study using a new imaging method according to the IDEAL criteria. 10th Northern Congress of Urology, Berlin 2016, HF7.10

Ecke TH, Arndt C, Gützlaff S, Lux O, Stephan C, Otto T, Hallmann S, Gerullis H. Results of a multicenter-study for UBC® Rapid as marker for urinary bladder cancer with focus on high risk tumours. Lecture, Suomen Urologiyhdistyksen Talvipäivät 2016, Turku, Finland, 12.02.2016.

Selinski S, Geis BC, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Salem J, Moormann O, Niedner H, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-acetyltransferase 2 (NAT2) and relapse-free time in bladder cancer patients. In: Deutscher Forschungsverbund Blasenkarzinom e. V.: Symposium des Deutschen Forschungsverbundes Blasenkarzinom e. V.. Düsseldorf, Feb. 19-20, 2016. program and abstracts (p. 15). Düsseldorf, 2016

Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Niedner H, Hengstler JG, Otto T, Golka K. N-acetyltransferase 1*10 genotype and urinary bladder carcinoma. In: DGAUM, Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e.V. (Ed.): 56th Annual Scientific Meeting 2016 "Resources and stressors in the world of work. Molecular occupational medicine. Occupational health management." Program and abstracts of presentations and posters, Munich, March 09-11, 2016 (p 106). Stuttgart: Gentner Verlag, 2016

Gerullis, H, Barski D, Boros M, Klosterhalfen B, Ramon A, Eimer C, Otto T. Coating of meshes with autologous plasma. On the IDEAL path from bench to bedside. 10th North Congress Urology, Berlin 2016, HF7.10

Barski D, Gerullis H, Ecke T, Klinge U, Boros M, Bader W, Puppe F, Otto T. Registry of urogynecological implants: Development of an online platform according to the IDEAL review method of surgical innovations. Forum Urodynamic,

Rostock 2016, Abstract 17

Barski D, Gerullis H, Otto T. Systematic comparison of complications after vaginal descensus correction in the anterior compartment with native tissue and mesh. 61st Annual Meeting of the North Rhine-Westphalia Society of Urology,

NRWGU 2015, Cologne, P 1.24

Winter A, Sirri E, Jansen L, Kieschke J, Gondos A, Holleczek B, Emrich K, Waldmann A, Brenner H for the GEKID Cancer Survival Group. Development of relative 5- and 10-year survival and stage distribution in prostate cancer in the PSA era: a population-based comparison between Germany and the USA. 67th Congress of the German Society of Urology, Hamburg. 2015, 23.-26.09.

Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Hengstler J, Otto T, Golka K. NAcetyltransferase 1*10 genotype in bladder cancer patients. Environmental Toxicology in North Rhine-Westphalia, Germany - Interdisciplinary research activities in toxicology, statistic, hygiene and medicine. Scientific symposium, Dortmund, May 7-8, 2015. abstracts (p 60). Dortmund: IfADo, 2015

Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Niedner H, Hengstler JG, Golka K, Otto T. Influence of N-acetyltransferase 1*10 genotype on urinary bladder carcinoma risk. 62nd Annual Meeting of the North Rhine-Westphalia Society of Urology, NRWGU 2015, Münster, P 3.6.

Ecke TH, Arndt C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. New results of a multicenter-study for urinary bladder cancer antigen (UBC) rapid as marker for urinary bladder cancer. Poster, ESUR-SBUR15, 11th World Congress Meeting on Urological Research, Nijmegen, The Netherlands, 11.09.2015.

Ecke TH, Arndt C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. New Results of a Multicentre-Study for UBC rapid as Marker for Urinary Bladder Cancer. Poster, 42.

Congress of the ISOBM, Zakopane, Poland, 04.10.2015

Barski D, Gerullis H, Georgas E, Klosterhalfen B, Borors M, Otto T. Coating of mesh graftsfor prolapse and urinary incontinence repair with autologous plasma: 1-year results. Annual Meeting of the International urogynecological association (IUGA), Nice, 2015, Abstract 316.

Barski D, Georgas E, Gerullis H, Heidari M, Quast S, Karig R, Bagner JW, Otto W, Otto T. The ileal couch - A new form of urinary diversion. 60th Annual Meeting of the North Rhine-Westphalia Society of Urology, NRWGU 2014, Düsseldorf, V 2.4.

Gerullis H, Georgas E, Barski D, Boros M, Klosterhalfen B, Lammers B, Eimer E, Ramon A, OttoT. A novel approach for assessment and improvement of surgical meshes. 36th International Congress of the European Hernia Society, Edinburgh, Scotland, Hernia 2014, Vol 18, Suppl 2, P171.

Barski D, Gerullis H, Otto T. Systematic review and classification of complications after anterior, posterior, apical and combined vaginal mesh implantation for prolapse repair. International Continence Society Annual Meeting 2014, Rio de Janeiro, Abstract 362.

Barski D, Gerullis H, Georgas E, Boros M, Klosterhalfen B, Lammers B, Otto T. Modification of mesh materials for prolapse and urinary incontinence repair by autologous plasma coating: a feasibility trial. International Continence Society Annual Meeting 2014, Rio de Janeiro, Abstract 432 .

Barski D, Joukhadar R, Solomeyer E, Klinge U, Puppe F, Gerullis H, Otto T. Register of urogynecological implants - a German initiation trial. International Continence Society Annual Meeting 2014, Rio de Janeiro, Abstract 475 .

Barski D, Gerullis H, Georgas E, Steven D, Schwartmann K, Otto T. Nephrocutaneous bypass for ureteral obstruction. 60th Annual Meeting of the North Rhine-Westphalia Society of Urology, NRWGU 2014, Düsseldorf, P 2.52.

Barski D, Georgas E, Gerullis H, Karig R, Bagner JW, Quast S, Otto T. Prospective.

Investigation on the influence of multiperforated catheters in radical retropubic prostatic vesiculectomy (RRP). 60th Annual Meeting of the North Rhine-Westphalian Society of Urology, NRWGU 2014, Düsseldorf, V 5.5.

Gerullis H, Eimer C., Georgas E., Barski D., Otto T. Combination therapy with vinflunine and pazopanib in advanced urothelial carcinoma after platinum failure Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Oncology 2013, Vienna, V415.

Make an appointment
We are happy to accept your appointment request by phone or email:

Team

Priv.-Doz. Dr. Dr. Holger Gerullis

Priv.-Doz. Dr. Dr. Holger Gerullis

Specialist in urology, medical tumor therapy and palliative medicine

Scientific contributions and publications